153 related articles for article (PubMed ID: 3566833)
21. Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
Izumi T; Iwamoto N; Kitaichi Y; Kato A; Inoue T; Koyama T
Eur J Pharmacol; 2007 Jun; 565(1-3):105-12. PubMed ID: 17400208
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. II: Effects on the cardiovascular system and smooth muscle organs.
Osada E; Murai T; Ishizaka Y; Sanai K
Arzneimittelforschung; 1984; 34(11A):1641-51. PubMed ID: 6152157
[TBL] [Abstract][Full Text] [Related]
23. [General pharmacological studies on tramadol, a potent analgetic agent (author's transl)].
Osterloh G; Friderichs E; Felgenhauer F; Günzler WA; Henmi Z; Kitano T; Nakamura M; Hayashi H; Ishii I
Arzneimittelforschung; 1978; 28(1a):135-51. PubMed ID: 305247
[TBL] [Abstract][Full Text] [Related]
24. N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) cyclohexanecarboxamide: a novel pre- and postsynaptic 5-hydroxytryptamine(1A) receptor antagonist active on the lower urinary tract.
Leonardi A; Guarneri L; Poggesi E; Angelico P; Velasco C; Cilia A; Testa R
J Pharmacol Exp Ther; 2001 Dec; 299(3):1027-37. PubMed ID: 11714892
[TBL] [Abstract][Full Text] [Related]
25. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
27. Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.
Simiand J; Keane PE; Barnouin MC; Keane M; Soubrié P; Le Fur G
Fundam Clin Pharmacol; 1993; 7(8):413-27. PubMed ID: 7904976
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action.
Lenke D; Gries J; Kretzschmar R
Arzneimittelforschung; 1981; 31(9a):1558-65. PubMed ID: 7197970
[TBL] [Abstract][Full Text] [Related]
29. Neuropharmacological profile of MD 780515, a new reversible inhibitor of type A monoamine oxidase.
Jalfre M; Bucher B; Coston A; Mocquet G; Porsolt RD
Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):194-221. PubMed ID: 6129835
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
[TBL] [Abstract][Full Text] [Related]
31. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase.
Mocaër E; Rettori MC; Kamoun A
Clin Neuropharmacol; 1988; 11 Suppl 2():S32-42. PubMed ID: 3180116
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MAO and GABA: probable mechanisms for antidepressant-like activity of Nardostachys jatamansi DC. in mice.
Dhingra D; Goyal PK
Indian J Exp Biol; 2008 Apr; 46(4):212-8. PubMed ID: 18512329
[TBL] [Abstract][Full Text] [Related]
34. 5-HT uptake inhibitors: psychopharmacological and neurobiochemical criteria of selectivity.
Maître L; Baumann PA; Jackel J; Waldmeier PC
Adv Biochem Psychopharmacol; 1982; 34():229-46. PubMed ID: 6215834
[No Abstract] [Full Text] [Related]
35. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological evaluation of 3-(N-3,3-diphenylpropyl-N-methyl)-aminopropan-1-ol-hydrochloride (PF-82), a new type of antidepressant drug.
Shimizu M; Hirooka T; Karasawa T; Masuda Y; Oka M
Arzneimittelforschung; 1974 Feb; 24(2):166-73. PubMed ID: 4207353
[No Abstract] [Full Text] [Related]
37. Light-dark phase differences in behavioral effects of moclobemide in rats.
Górka Z; Zajaczkowski W
Pol J Pharmacol Pharm; 1991; 43(3):177-86. PubMed ID: 1961692
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of hepzidine maleate: 4-[10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-1-methylpiperidine hydrogen maleate (BS 7051).
Funcke AB; Louwerse WJ; Tersteege HM; Harms AF; Nauta WT
Arch Int Pharmacodyn Ther; 1967 Jun; 167(2):334-68. PubMed ID: 6069940
[No Abstract] [Full Text] [Related]
39. Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).
Gogerty JH; Penberthy C; Iorio LC; Trapold JH
Arch Int Pharmacodyn Ther; 1975 Apr; 214(2):285-307. PubMed ID: 1171662
[TBL] [Abstract][Full Text] [Related]
40. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
